A status granted by a medicines regulator, such as the US FDA, to encourage development of treatments for rare conditions, typically bringing incentives such as extended market exclusivity or reduced regulatory fees. Orphan drug designation is a development incentive, not a marketing approval, so a substance can hold orphan drug designation for a condition without ever being approved to treat it, and the two should not be described as if they mean the same thing.
Peptides where this matters
-
Thymosin Alpha-1Thymalfasin
Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.
ModerateNot licensed in the UK
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.